Bearing in mind all results obtained, we decided to test the compound in functional and tailor-made cellular assays in order to access its capacity to stop proliferation of specific cancer cells in which DPPIV plays an important role acting particularly on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and to compare these results with other relevant cancer cell lines. The gene discussed is GIP; the disease is cancer.